Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
FIGHT-202
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
- NCT02924376 ↗
- Completed
- Incyte Corporation
- Deep
We haven't built an HCP commentary report on FIGHT-202 (pemigatinib in previously treated advanced or metastatic cholangiocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on FIGHT-202 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 31 | |
| Podcasts | 8 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Cholangiocarcinoma
- Interventions
- Pemigatinib
- Arms
- Cohort A Pemigatinib · Experimental
- Cohort B Pemigatinib · Experimental
- Cohort C Pemigatinib · Experimental
- Enrollment
- 147
- Primary outcomes
- Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions
- Sponsor
- Incyte Corporation
- Start
- Jan 16, 2017
- Primary completion
- Feb 1, 2022
- Results posted
- Yes
- Registry record
- NCT02924376 · updated Aug 14, 2025
Publications
linked from the registry- Patel TH, Marcus L, Horiba MN, Donoghue M, Chatterjee S, Mishra-Kalyani PS, Schuck RN, Li Y, Zhang X, Fourie Zirkelbach J, Charlab R, Liu J, Yang Y, Lemery SJ, Pazdur R, Theoret MR, Fashoyin-Aje LA. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement. Clin Cancer Res. 2023 Mar 1;29(5):838-842. doi: 10.1158/1078-0432.CCR-22-2036. PubMed 36206041
- Bibeau K, Feliz L, Lihou CF, Ren H, Abou-Alfa GK. Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response. JCO Precis Oncol. 2022 Apr;6:e2100414. doi: 10.1200/PO.21.00414. PubMed 35544727
- Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Feliz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20. PubMed 32203698